
News|Articles|March 1, 2005
Exenatide: A novel incretin mimetic hormone for the treatment of type 2 diabetes
A number of clinical approaches are utilized in managing the overlapping aspects of poor glycemic control in patients with type 2 diabetes. Exenatide (Amylin/Lilly), a novel drug in a new medication class known as the incretin mimetic agents, offers a new mechanism to achieve glycemic control.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
4 things to know about the Abarca/LucyRx merger
2
Hospitals facing financial headwinds can't afford to ignore the mounting threats to 340B
3
EHR-based risk calculator reduces 3-year diabetes risk in patients with prediabetes
4
Healthcare's AI push is creating a new workforce challenge
5
































